Abstract
The authors examined the effect of pravastatin 40 mg daily on the progression of ischemic brain lesions using repeated brain MRI. After a mean treatment period of 33 months, there was an increase in total ischemic lesion load of 1.1 cm3 (p < 0.001) in the 270 placebo-treated subjects and 1.1 cm3 (p < 0.001) in the 265 pravastatin-treated subjects. There was no difference between the two treatment groups (p = 0.73).
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Brain Ischemia / drug therapy*
-
Brain Ischemia / metabolism
-
Brain Ischemia / pathology
-
Cerebral Infarction / drug therapy*
-
Cerebral Infarction / metabolism
-
Cerebral Infarction / pathology
-
Cholesterol, LDL / blood
-
Cholesterol, LDL / drug effects
-
Disease Progression
-
Female
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
-
Intracranial Arteriosclerosis / drug therapy
-
Intracranial Arteriosclerosis / metabolism
-
Intracranial Arteriosclerosis / prevention & control
-
Magnetic Resonance Imaging
-
Male
-
Nerve Fibers, Myelinated / drug effects*
-
Nerve Fibers, Myelinated / pathology
-
Pravastatin / administration & dosage*
-
Prospective Studies
-
Telencephalon / drug effects*
-
Telencephalon / metabolism
-
Telencephalon / pathology
-
Treatment Failure
Substances
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pravastatin